Development and validation of HPLC-MS/MS technique for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit plasma
Open Access
- 24 April 2026
- journal article
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Abstract
Introduction. BBP2023 is a new drug candidate of the sydnonymine group with cerebral vasodilating activity and procognitive properties. The pharmacological effects of BBP2023 are due to the presence of active metabolites. To conduct pharmacokinetic studies at the preclinical stage, it is necessary to develop a bioanalytical method for the determination of BBP2023 and its metabolites in rabbit blood plasma. Aim. Development and validation of a chromatography-mass spectrometric method for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit blood plasma. Materials and methods. Quantitative determination of BBP2023 in rabbit blood plasma was performed by HPLC-MS/MS. The biomaterial sample preparation was based on the method of protein precipitation with methanol. Chromatographic separation was performed with a mixture of deionized water and acetonitrile in a gradient mode on a ZORBAX Eclipse XDB-C18 analytical column (4.6 × 50 mm, 5 μm) using an Agilent 1260 Infinity II chromatograph. Detection was performed in the MRM mode using an AB Sciex QTRAP 3200 MD mass spectrometer. N-(ethoxycarbonyl)-3-(4-methylpentan-2-yl)sydnonymine was used as the internal standard. Results and discussion. The method for sample preparation of rabbit blood plasma has been developed, optimal conditions for chromatography and detection of the studied compound and its metabolites have been selected. The bioanalytical method has been validated according to the following parameters: selectivity, matrix effect, recovery rate, carry-over effect, linearity of the calibration range, lower limit of quantitative determination, intraand inter-run accuracy and precision, as well as stability of analytes and the internal standard at the analysis stages. Conclusion. A method for the quantitative determination of a new derivative of sydnonymine BBP2023 and its metabolites in rabbit blood plasma using HPLC-MS/MS has been developed and validated. The confirmed analytical ranges for BBP2023, BBP2023 A and BBP2023 C were 5.0–500.0 ng/ml (5.0–1000.0 ng/ml for geranamine). The method was used in the analytical part of the preclinical pharmacokinetic study of BBP2023 in rabbits.Keywords
This publication has 20 references indexed in Scilit:
- Sydnonimines: synthesis, properties and applications in chemical biologyChemical Communications, 2025
- A systematic review and evaluation of post-stroke depression clinical practice guidelinesJournal of Stroke and Cerebrovascular Diseases, 2023
- Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairmentActa Neuropathologica Communications, 2023
- Cerebral Small Vessel Disease and Depression Among Intracerebral Hemorrhage SurvivorsStroke, 2021
- Pharmacology of Drugs Used as StimulantsThe Journal of Clinical Pharmacology, 2021
- Recurrent Ischemic Stroke – A Systematic Review and Meta-AnalysisJournal of Stroke and Cerebrovascular Diseases, 2021
- Design, Synthesis, and Biological Evaluation of Organic Nitrite (NO2–) Donors as Potential Anticerebral Ischemia AgentsJournal of Medicinal Chemistry, 2021
- Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysisNeurological Sciences, 2021
- Post-stroke emotionalism: a qualitative investigationDisability and Rehabilitation, 2019
- Potential involvement of the extracranial venous system in central nervous system disorders and agingBMC Medicine, 2013